<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638846</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0801</org_study_id>
    <secondary_id>CTOR-501</secondary_id>
    <nct_id>NCT00638846</nct_id>
  </id_info>
  <brief_title>Performance of Two Silicone Hydrogel Toric Contact Lenses</brief_title>
  <official_title>Multi-Center Evaluation Of Two Silicone Hydrogel Toric Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical performance of two toric contact lenses in a 2-week, single masked
      (subject), daily wear, randomized, bilateral, parallel group study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lens Orientation</measure>
    <time_frame>1 minute after insertion</time_frame>
    <description>Proportion of eyes with lens orientation within 5 degrees of optimal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Stability</measure>
    <time_frame>10-15 minutes after insertion</time_frame>
    <description>Lens stability is measured as the amount of rotation induced from blink after the lens has settled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Comfort</measure>
    <time_frame>2 weeks of lens wear</time_frame>
    <description>Subjective comfort was derived from a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response. &gt;0 = comfortable, &lt; 0 = uncomfortable. Combined measures from Week 1 and Week 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Fit Lens</measure>
    <time_frame>after lens insertion</time_frame>
    <description>Time required for the optometrist to fit the lens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Lens Vision</measure>
    <time_frame>measured at 1 and 2 weeks</time_frame>
    <description>A weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response was used to derive vision outcomes. &gt;0 = satisfactory vision, &lt; 0 = unsatisfactory vision. Analysis is performed on combined 1 week and 2 week data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Corneal Staining</measure>
    <time_frame>After 2 weeks use</time_frame>
    <description>National Eye Institute 0-3 Scale: Grade 0 = Normal, Grade 1 = Mild, superficial stippling, Grade 2 = Moderate, punctuate staining including superficial abrasion of the cornea, Grade 3 = Severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Vision Correction</condition>
  <arm_group>
    <arm_group_label>senofilcon A toric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>senofilcon A, daily wear, toric contact lens worn for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balafilcon A toric</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>balafilcon A, daily wear, toric contact lens worn for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A toric</intervention_name>
    <description>silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)</description>
    <arm_group_label>senofilcon A toric</arm_group_label>
    <other_name>ACUVUE OASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balafilcon A toric</intervention_name>
    <description>silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)</description>
    <arm_group_label>balafilcon A toric</arm_group_label>
    <other_name>PureVision Toric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be between 18 and 45 years of age.

          -  Sign Written Informed Consent (See separate document).

          -  Be an existing successful daily wear toric soft contact lens.

          -  Require a visual correction in both eyes (monovision or uniocular fitting is NOT
             allowed).

          -  Does not require presbyopic correction (can read J1 @ normal reading distance).

          -  Have a sphere requirement in the range -1.00 and -5.00D (-5.25D refractive)

          -  Have refractive astigmatism between 0.75D and 2.50D in both eyes.

          -  Achieve visual acuity of 20/30 or better in each eye with spherical distance
             correction.

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

               -  No amblyopia.

               -  No evidence of lid abnormality or infection.

               -  No conjunctival abnormality or infection.

               -  No clinically significant slit lamp findings (i.e. stromal edema,
                  vascularisation, infiltrates or abnormal opacities).

               -  No other active ocular disease.

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularisation,
             tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of
             the cornea that would contraindicate contact lens wear.

          -  Corneal staining Grade 3 in more than one region.

          -  Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately
             prior to enrolment for this study.

          -  Abnormal lacrimal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  Polymethyl methacrylate (PMMA) or Rigid Gas Permeable (RGP) lens wear in the previous
             8 weeks

          -  Extended lens wear in last 3 months.

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Diabetic.

          -  Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease
             (e.g., HIV).

          -  Pregnancy, lactating or planning a pregnancy at the time of enrolment.

          -  Participation in any concurrent clinical trial or in last 60 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme YOung, MPhil PhD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Camp Eye Care Clinic</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James R. Dugue, O.D.</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Executive Park Eye Care</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ted Brink and Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grene Vision Group</name>
      <address>
        <city>Neodesha</city>
        <state>Kansas</state>
        <zip>66757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Eyecare, PC</name>
      <address>
        <city>Raytown</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. James Brobst</name>
      <address>
        <city>Florence</city>
        <state>New Jersey</state>
        <zip>08518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fine Eye Care Associates</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Ophthalmology Associates</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selden Eyecare LLC</name>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nittany Eye Associates</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David W. Ferris and Associates</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Larry Menning</name>
      <address>
        <city>Chamberlain</city>
        <state>South Dakota</state>
        <zip>57325-0490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wishnow-Sugar Vision Group</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. William Bogus</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midlothian Optometric Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Specialists, Ltd.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye &amp; Contact Lens Clinic</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matus Eyecare</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <results_first_submitted>June 18, 2010</results_first_submitted>
  <results_first_submitted_qc>June 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2010</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>toric contact lenses</keyword>
  <keyword>vision</keyword>
  <keyword>comfort</keyword>
  <keyword>toric fit characteristics</keyword>
  <keyword>slit lamp findings</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon A Toric</title>
          <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
        <group group_id="P2">
          <title>Balafilcon A Toric</title>
          <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>lens issue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Senofilcon A Toric</title>
          <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
        <group group_id="B2">
          <title>Balafilcon A Toric</title>
          <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="276"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.81" spread="6.99"/>
                    <measurement group_id="B2" value="30.13" spread="7.69"/>
                    <measurement group_id="B3" value="29.97" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender of 2 subjects assigned to balafilcon A is unknown.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lens Orientation</title>
        <description>Proportion of eyes with lens orientation within 5 degrees of optimal</description>
        <time_frame>1 minute after insertion</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol. The data represents 274 eyes that wore senofilcon A lenses and 278 eyes that wore balafilcon A lenses.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Orientation</title>
          <description>Proportion of eyes with lens orientation within 5 degrees of optimal</description>
          <population>Analysis was performed on participants who completed the study per protocol. The data represents 274 eyes that wore senofilcon A lenses and 278 eyes that wore balafilcon A lenses.</population>
          <units>proportion of eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is senofilcon A toric is superior to balfilcon A toric by having less degrees of rotation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.739</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.136</ci_lower_limit>
            <ci_upper_limit>1.739</ci_upper_limit>
            <estimate_desc>Odds ratio was senofilcon A toric / balafilcon A toric</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Stability</title>
        <description>Lens stability is measured as the amount of rotation induced from blink after the lens has settled.</description>
        <time_frame>10-15 minutes after insertion</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Stability</title>
          <description>Lens stability is measured as the amount of rotation induced from blink after the lens has settled.</description>
          <population>Analysis was performed on participants who completed the study per protocol.</population>
          <units>proportion of eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89"/>
                    <measurement group_id="O2" value="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is that senofilcon A toric is superior to balafilcon A toric by having less degrees of instability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.138</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.624</ci_lower_limit>
            <ci_upper_limit>1.138</ci_upper_limit>
            <estimate_desc>Odds ratio was senofilcon A toric/balafilcon A toric</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fit Lens</title>
        <description>Time required for the optometrist to fit the lens.</description>
        <time_frame>after lens insertion</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fit Lens</title>
          <description>Time required for the optometrist to fit the lens.</description>
          <population>Analysis was performed on participants who completed the study per protocol.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2789" spread="0.2045"/>
                    <measurement group_id="O2" value="7.4095" spread="0.1994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is that senofilcon A toric is superior to balafilcon A toric by having less time required to fit.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1307</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2856</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1307</ci_lower_limit>
            <ci_upper_limit>-0.5680</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as senofilcon A toric minus balafilcon At toric.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Lens Vision</title>
        <description>A weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response was used to derive vision outcomes. &gt;0 = satisfactory vision, &lt; 0 = unsatisfactory vision. Analysis is performed on combined 1 week and 2 week data.</description>
        <time_frame>measured at 1 and 2 weeks</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Lens Vision</title>
          <description>A weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response was used to derive vision outcomes. &gt;0 = satisfactory vision, &lt; 0 = unsatisfactory vision. Analysis is performed on combined 1 week and 2 week data.</description>
          <population>Analysis was performed on participants who completed the study per protocol.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1942" spread="0.09637"/>
                    <measurement group_id="O2" value="-0.1738" spread="0.09716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is that senofilcon A is superior to balafilcon A.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3680</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1331</dispersion_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07001</ci_lower_limit>
            <ci_upper_limit>0.3680</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as senofilcon A toric minus balafilcon A toric.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Corneal Staining</title>
        <description>National Eye Institute 0-3 Scale: Grade 0 = Normal, Grade 1 = Mild, superficial stippling, Grade 2 = Moderate, punctuate staining including superficial abrasion of the cornea, Grade 3 = Severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
        <time_frame>After 2 weeks use</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Corneal Staining</title>
          <description>National Eye Institute 0-3 Scale: Grade 0 = Normal, Grade 1 = Mild, superficial stippling, Grade 2 = Moderate, punctuate staining including superficial abrasion of the cornea, Grade 3 = Severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
          <population>Analysis was performed on participants who completed the study per protocol.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0919" spread="0.0178"/>
                    <measurement group_id="O2" value="0.1607" spread="0.0178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is that senofilcon A toric is superior to balafilcon A toric by having a lower grade fo corneal staining.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is -0.4.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0688</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1648</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0688</ci_lower_limit>
            <ci_upper_limit>-0.0197</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as senofilcon A toric minus balafilcon A toric.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Comfort</title>
        <description>Subjective comfort was derived from a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response. &gt;0 = comfortable, &lt; 0 = uncomfortable. Combined measures from Week 1 and Week 5.</description>
        <time_frame>2 weeks of lens wear</time_frame>
        <population>Analysis was performed on participants who completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
            <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Balafilcon A Toric</title>
            <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Comfort</title>
          <description>Subjective comfort was derived from a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response. &gt;0 = comfortable, &lt; 0 = uncomfortable. Combined measures from Week 1 and Week 5.</description>
          <population>Analysis was performed on participants who completed the study per protocol.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1942" spread="0.09637"/>
                    <measurement group_id="O2" value="-0.1738" spread="0.09716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis is that senofilcon A toric is superior to balafilcon A toric.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.3680</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1331</dispersion_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07001</ci_lower_limit>
            <ci_upper_limit>0.3680</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as senofilcon A toric minus balafilcon A toric.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A Toric</title>
          <description>senofilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
        <group group_id="E2">
          <title>Balafilcon A Toric</title>
          <description>balafilcon A toric contact lens. Analysis includes participants that completed the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody OD</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

